Topic: myelodysplastic syndrome (MDS)
The deal that will see Bristol-Myers Squibb subsume Celgene is all but done, and today Celgene delivered some positive optics for its would-be parent.
BMS and Eisai spinoff H3 Biomedicine will conduct research aimed at developing immune therapies for cancer using the latter’s RNA-splicing platform.
A phase 3 trial of Celgene’s luspatercept in beta-thalassemia has hit its primary goal, teeing it up for an FDA filing in the first half of next year.
Janssen is quitting its imetelstat partnership with Geron, sending the latter's stock down 68% in premarket trading.
Acceleron and Celgene have the second phase 3 trial they wanted for beta thalassemia drug luspatercept, setting up filings in the U.S. and Europe.
Acceleron Pharma unveiled data showing luspatercept reduced the need for red blood cell transfusions in patients with myelodysplastic syndromes.
Acceleron’s chief medical officer Matthew Sherman, M.D., will be leaving the company—after results come in on its lead candidate luspatercept.
The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.